CollPlant Biotechnologies (CLGN) Net Cash Flow (2018 - 2026)

CollPlant Biotechnologies has reported Net Cash Flow for 9 years, with the latest figure at -$1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 13.7% year-over-year to -$1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$9.6 million (up 22.97% YoY), and the FY2025 full-year result was -$6.3 million, up 56.62% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$1.3 million, up from -$2.9 million in the prior quarter.
• The five-year high for Net Cash Flow was $28.1 million in Q1 2022, with the low at -$13.6 million in Q4 2022.
• Historically, Net Cash Flow has averaged -$1.3 million across 5 years, with a median of -$2.9 million in 2025.
• Annual changes were most pronounced in 2023 — Net Cash Flow surged 292.44% — and 2024, when it tumbled 153.16%.
• CollPlant Biotechnologies' Net Cash Flow stood at -$13.6 million in 2022, then jumped by 80.02% to -$2.7 million in 2023, then slipped by 29.63% to -$3.5 million in 2024, then advanced by 16.24% to -$2.9 million in 2025, then soared by 54.71% to -$1.3 million in 2026.
• The last three Net Cash Flow figures came in at -$1.3 million (Q1 2026), -$2.9 million (Q4 2025), and -$2.9 million (Q3 2025), per Business Quant data.